Please login to the form below

Not currently logged in
Email:
Password:

Seattle Generics

This page shows the latest Seattle Generics news and features for those working in and with pharma, biotech and healthcare.

Seattle Genetics signs $2bn deal for Immunomedics' cancer drug

Seattle Genetics signs $2bn deal for Immunomedics' cancer drug

Immunomedics has signed up Seattle Genetics as the licensee for its triple-negative breast cancer (TNBC) drug IMMU-132, getting $300m upfront and another $1.7bn in possible milestone payments. ... Seattle Genetics will handle the running of a proposed

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics